REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations

被引：0
|
作者：
Yu, Helena Alexandra
Besse, Benjamin
Nishio, Makoto
Cheng, Ying
Wei, Li
Wacheck, Volker
Heymach, John
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Inst Gustave Roussy, Villejuif, France
[3] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[4] Jilin Canc Hosp, Changchun, Peoples R China
[5] Taiho Oncol Inc, Princeton, NJ USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8671
引用
收藏
页数：1
相关论文
共 50 条
  • [1] REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
    Nishio, Makoto
    Yu, Helena Alexandra
    Besse, Benjamin
    Cheng, Ying
    Tan, Daniel Shao-Weng
    Wei, Li
    Wacheck, Volker
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS219 - TPS219
  • [2] REZILIENT3: Phase 3 Study of Zipalertinib plus Chemotherapy in Previously Untreated, Advanced Nonsquamous NSCLC Patients with EGFR Exon 20 Insertions
    Yu, Helena A.
    Besse, Benjamin
    Nishio, Makoto
    Cheng, Ying
    Wei, Li
    Wacheck, Volker
    Heymach, John V.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E40 - E40
  • [3] REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations
    Yu, Helena Alexandra
    Besse, Benjamin
    Nishio, Makoto
    Wei, Ying Cheng Li
    Wacheck, Volker
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Phase III study of zipalertinib plus fi rst-line (1L) platinum- based chemotherapy in patients (pts) with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion (ex20ins) mutations (REZILIENT3): Safety lead-in results
    Kurata, T.
    Fujiwara, Y.
    Naoki, K.
    Viteri, S.
    Inoue, T.
    Hangai, N.
    Wei, L.
    Kawabata, R.
    Wacheck, V.
    Nishio, M.
    ANNALS OF ONCOLOGY, 2024, 35
  • [5] Epidermal growth factor receptor (EGFR) testing and treatment patterns associated with diagnosis of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) in the US
    Piotrowska, Z.
    Lin, M.
    Yin, Y.
    Curran, E.
    Crossland, V.
    Wu, Y.
    Ou, S-H. I.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1011 - S1011
  • [6] Epidermal growth factor receptor (EGFR) mutation testing and immunotherapy (IO) use associated with diagnosis of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) in the US
    Ou, S-H. I.
    Lin, M.
    Yin, Y.
    Curran, E.
    Churchill, E.
    Piotrowska, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S1581 - S1581
  • [7] REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC
    Heymach, John V.
    Yu, Helena A.
    Besse, Benjamin
    Cheng, Ying
    Tan, Daniel S. W.
    Wei, Li
    Wacheck, Volker
    Nishio, Makoto
    FUTURE ONCOLOGY, 2025, 21 (05) : 549 - 556
  • [8] Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)
    Trigo, J.
    Cho, B. C.
    Park, K.
    Girard, N.
    Viteri, S.
    Garrido, P.
    Krebs, M. G.
    Thayu, M.
    Knoblauch, R. E.
    Xie, J.
    Bauml, J. M.
    Schnepp, R. W.
    Londhe, A.
    Mahadevia, P.
    Leighl, N.
    ANNALS OF ONCOLOGY, 2022, 33 : S38 - S39
  • [9] Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins).
    Ou, Sai-Hong Ignatius
    Prawitz, Thibaud
    Lin, Huamao Mark
    Hong, Jin-Liern
    Tan, Minal
    Proskorovsky, Irina
    Hernandez, Luis
    Jin, Shu
    Zhang, Pingkuan
    Lin, Jianchang
    Patel, Jyoti D.
    Nguyen, Danny
    Neal, Joel W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions
    Piotrowska, Zofia
    Tan, Daniel Shao-Weng
    Smit, Egbert F.
    Spira, Alexander I.
    Soo, Ross A.
    Nguyen, Danny
    Lee, Victor Ho-Fun
    Yang, James Chih-Hsin
    Velcheti, Vamsidhar
    Wrangle, John M.
    Socinski, Mark A.
    Koczywas, Marianna
    Janik, John E.
    Jones, Jeffrey
    Yu, Helena Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (26) : 4218 - +
12345